Tungsten, courtesy of Enough Project via YouTubeAn appellate court Monday struck down part of the conflict-minerals rule, leaving SEC-reporting companies wondering what disclosures to include in their conflict minerals reports due on May 31.
Search Results for: label/Medtronic – Page 2
For those who missed any of the FCPA enforcement news during the recent hyper-active stretch, here’s what happened: July 28 — Label-maker Avery Dennison Corporation resolved civil and administrative charges brought by the Securities and Exchange Commission. The SEC filed settled enforcement actions in the United States District Court for the Central District of California […]
Label-maker Avery Dennison Corporation, whose compliance problems in China were described in an LA Times story last January, has resolved civil and administrative charges brought by the Securities and Exchange Commission. The SEC filed settled enforcement actions in the United States District Court for the Central District of California charging Avery with violating the FCPA’s […]
This week, Wright Medical Group became the latest orthopedic device maker to disclose a government investigation into its overseas sales practices. The company’s Form 8-K said its principal operating subsidiary, Wright Medical Technology, Inc., received notice from the Securities and Exchange Commission of an informal investigation regarding potential violations of the Foreign Corrupt Practices Act. […]
Medical device maker ev3 Inc. agreed to pay $1.25 million to resolve allegations that it caused some hospitals to unnecessarily admit Medicare patients for an outpatient procedure to open hardened arteries, the Justice Department said Thursday.
Shire Pharmaceuticals LLC will pay $56 million to settle allegations that its marketing and promotion of several drugs violated the False Claims Act, the Justice Department said Wednesday.
Tantalum, courtesy of Enough Project via YouTubeThe federal appeals court for the D.C. circuit issued its opinion Monday in National Association of Manufacturers (NAM), et al., v. Securities and Exchange Commission that partially struck down the SEC’s conflict minerals disclosure rule.